News
Hikma Pharmaceuticals has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a ...
Hikma Pharmaceuticals said on Thursday that it has entered into a preliminary $50m class settlement agreement that resolves ...
Hikma Pharmaceuticals Plc reached a $50 million deal to settle claims it colluded with other drugmakers to delay the generic version of brand-name narcolepsy drug Xyrem.
(Alliance News) - Hikma Pharmaceuticals PLC on Thursday announced it has reached a settlement deal for up to USD50 million in cash for litigation brought against the firm in relation to its narcolepsy ...
Jazz Pharmaceuticals PLC (JAZZ) reports robust Q1 2025 performance with significant revenue growth in neuroscience, despite a ...
Jazz Pharmaceuticals ( NASDAQ: JAZZ) shares fell after the market on Tuesday as the company lowered its full year bottom-line expectation, to reflect the impact of the Chimerix deal and certain Xyrem ...
It posted quarterly Xyrem net product sales down 42% to $37.2M, while Xywav net product sales rose 9% to $344.8M. The stock is down 5.6% in post market trading.
2d
Zacks.com on MSNHere's What Key Metrics Tell Us About Jazz (JAZZ) Q1 EarningsAlthough the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street ...
Jazz attributed the earnings miss primarily to a $172 million expense related to Xyrem antitrust litigation settlements. This impacted GAAP and non-GAAP results by $146.3 million after tax, or $2.34 ...
We recently published a list of Billionaire Ray Dalio’s Bridgewater’s 10 Stock Picks with Huge Upside Potential.
Xywav® and Epidiolex® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 -- Completed submission of sNDA for Zepzelca® in 1L ES-SCLC -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results